|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
InVasc Therapeutics Initiates Phase IIa Proof of Concept Study with INV-144 in Patients with Chronic Kidney Disease
6/24/2011 9:32:51 AM
ATLANTA--(BUSINESS WIRE)--InVasc Therapeutics, Inc., announced today that it has initiated a Phase IIa, proof of concept (POC), clinical trial with INV-144, a combination drug of losartan with alpha Lipoic Acid (ALA), to slow the progression of chronic kidney disease (CKD) in hypertensive diabetic patients. The trial, which is being conducted under an IND in the United States, is a multi-center, randomized, double-blind, active-controlled study that will compare the treatment of patients with losartan alone versus losartan plus ALA. Each arm of the trial will enroll 40 patients. Losartan is already approved for the treatment of patients with CKD. ALA, a powerful antioxidant, is a widely used nutraceutical in the U.S.; and in Europe, it has been approved for treating diabetic peripheral neuropathy.
|
|
|
|
|
|
|
|
|
|
|